CDC recommends resuming use of Johnson & Johnson COVID-19 vaccine

A panel of advisers to the Centers for Disease Control and Prevention voted Friday to recommend resuming use of Johnson & Johnson's Janssen vaccine to protect against COVID-19. The shots are  expected to be accompanied by a new warning about an increased risk of rare but serious blood clots for adult women under 50.

A federal health official told the panel Friday that vaccinations could resume once the CDC director approves its recommendations and the Food and Drug Administration publishes an update to its emergency use authorization for the vaccine.  A total of three women have died from the clotting disorder after receiving the Janssen vaccine, out of 16 cases like it in total among women in the U.S, the CDC told its panel of advisers on Friday. Seven remain hospitalized and five have been released. Most were under the age of 50.